Andrew Sheets: How Will Markets React to a Workable Vaccine?
For markets, a vaccine may be the most significant sign the world may return to a more normal future. But what are markets pricing in currently?
2 Okt 20202min
Special Episode: COVID-19 Vaccine - Trials and Tribulations
COVID-19 vaccines are navigating through the last stage of clinical trials, but hurdles still lie ahead for efficacy, distribution and FDA approval.
1 Okt 20209min
Michael Zezas: It’s the Results That Count
How will markets react if final U.S. election results take days or weeks? Head of U.S. Public Policy Research Michael Zezas shares advice for investors.
30 Sep 20202min
Mike Wilson: Near-term Correction; Long-term Recovery?
The recent correction may have been inevitable given rising risks for fiscal stimulus, a potential COVID-19 second wave and the upcoming election. But a resolution to these hurdles may also be possible longer-term.
28 Sep 20203min
Andrew Sheets: Four Reasons to Remain Patient
Despite a needed correction in recent weeks, a suite of significant risks still hangs over U.S. markets. Chief Cross-Asset Strategist Andrew Sheets explains.
25 Sep 20202min
Michael Zezas: Unlikely Paths to Stimulus May Interest Investors
As hopes for an additional stimulus package wane in the run-up to the U.S. elections, some of the less likely paths to a deal may provide a way out of the current correction. Michael Zezas, Head of U.S. Public Policy Research, explains.
24 Sep 20202min
Mike Wilson: A Correction with Policy Roots
Action by Congress and the Fed, and its absence, has paved the way for the recent downturn in equities, putting markets back on a more sustainable footing. Chief Investment Officer Mike Wilson explains.
21 Sep 20203min
Andrew Sheets: The Uncertainty of the Fed’s New Certainty
This week, the Fed announced a new framework that could keep interest rates unusually low. So why did markets collectively yawn at the announcement?
18 Sep 20203min
